Registry remains little changed with the majoroity of the company held by the Top 20 actually a slight increase 57% last year compared to 62% as of this report. Addition of Lang Walker & AEIS has put a much tighter grip on the top echelon though with the Top 3 holders now with 40% of the company.
Phase II IV is still experiencing slow enrollment which i guess was expected as all other TBI trials of a similar nature have also been quite prolonged to meet enrollments.
Cohort (1/4) of 2566 has been completed - safe & well tolerated with no adverse effects. US ARMY has provided a further US$2.9M to fund support of the oral formulationas it remains high priority for them. Phase II 2nd half of 2012.
Retts Syndrome, PreIND meeting with FDA in May & Orphan Drug Designation requested, seeking to apply fast track designation after the approval of IND. Initiate enrollment late 2012.
Perseis antibody results now forecast for May release
Looks like a busy May ahead.
NEU Price at posting:
2.4¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)